Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

por Huang, Tzu-Ting, Su, Jung-Chen, Liu, Chun-Yu, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado 2017

CIP2A is a target of bortezomib in human triple negative breast cancer cells

por Tseng, Ling-Ming, Liu, Chun-Yu, Chang, Kung-Chi, Chu, Pei-Yi, Shiau, Chung-Wai, Chen , Kuen-Feng
Publicado 2012

Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition

por Hou, Duen-Ren, Huang, Ann-Chi, Shiau, Chung-Wai, Wang, Chun-Yi, Yu, Hui-Chuan, Chen, Kuen-Feng
Publicado 2013

Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome

por Yu, Hui-Chuan, Hou, Duen-Ren, Liu, Chun-Yu, Lin, Chen-Si, Shiau, Chung-Wai, Cheng, Ann-Lii, Chen, Kuen-Feng
Publicado 2013

Corrigendum to “Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells” [Neoplasia 14 (2012) 463–475]...

por Lin, Yu-Chin, Wu, Meng-Hsuan, Wei, Tzu-Tang, Chuang, Shu-Hui, Chen, Kuen-Feng, Cheng, Ann-Lii, Chen, Ching-Chow
Publicado 2017

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

por Liu, Chun-Yu, Tseng, Ling-Ming, Su, Jung-Chen, Chang, Kung-Chi, Chu, Pei-Yi, Tai, Wei-Tien, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado 2013

Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer()()

por Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Tai, Wei-Tien, Hung, Man-Hsin, Yang, Shung-Haur, Jiang, Jeng-Kai, Chen, Kuen-Feng
Publicado 2015

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

por Liu, Chun-Yu, Tseng, Ling-Ming, Su, Jung-Chen, Chang, Kung-Chi, Chu, Pei-Yi, Tai, Wei-Tien, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado 2017

Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer

por Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Tai, Wei-Tien, Hung, Man-Hsin, Yang, Shung-Haur, Jiang, Jeng-Kai, Chen, Kuen-Feng
Publicado 2016

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

por Hu, Ming-Hung, Chen, Li-Ju, Chen, Yen-Lin, Tsai, Ming-Shen, Shiau, Chung-Wai, Chao, Tzu-I, Liu, Chun-Yu, Kao, Jia-Horng, Chen, Kuen-Feng
Publicado 2017

SHP-1 is a target of regorafenib in colorectal cancer

por Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Lin, Hang, Hung, Man-Hsin, Chen, Yen-Lin, Huang, Jui-Wen, Tai, Wei-Tien, Yu, Hui-Chuan, Chen, Kuen-Feng
Publicado 2014

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells

por Su, Jung-Chen, Tseng, Ping-Hui, Hsu, Cheng-Yi, Tai, Wei-Tien, Huang, Jui-Wen, Ko, Ching-Huai, Lin, Mai-Wei, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai
Publicado 2014

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()

por Su, Jung-Chen, Tseng, Ping-Hui, Wu, Szu-Hsien, Hsu, Cheng-Yi, Tai, Wei-Tien, Li, Yong-Shi, Chen, I-Ting, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai
Publicado 2014

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A

por Hung, Man-Hsin, Wang, Cheng-Yi, Chen, Yen-Lin, Chu, Pei-Yi, Hsiao, Yung-Jen, Tai, Wei-Tien, Chao, Ting-Ting, Yu, Hui-Chuan, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado 2015

SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma

por Tai, Wei-Tien, Hung, Man-Hsin, Chu, Pei-Yi, Chen, Yao-Li, Chen, Li-Ju, Tsai, Ming-Hsien, Chen, Min-Husan, Shiau, Chung-Wai, Boo, Yin-Pin, Chen, Kuen-Feng
Publicado 2016

Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation

por Hung, Man-Hsin, Chen, Yao-Li, Chen, Li-Ju, Chu, Pei-Yi, Hsieh, Feng-Shu, Tsai, Ming-Hsien, Shih, Chih-Ting, Chao, Tzu-I, Huang, Chao-Yuan, Chen, Kuen-Feng
Publicado 2019

Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A

por Chao, Ting-Ting, Wang, Cheng-Yi, Chen, Yen-Lin, Lai, Chih-Cheng, Chang, Fang-Yu, Tsai, Yi-Ting, Chao, Chung-Hao H., Shiau, Chung-Wai, Huang, Yuh-Chin T., Yu, Chong-Jen, Chen, Kuen-Feng
Publicado 2014

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells

por Liu, Chun-Yu, Hung, Man-Hsin, Wang, Duen-Shian, Chu, Pei-Yi, Su, Jung-Chen, Teng, Tsung-Han, Huang, Chun-Teng, Chao, Ting-Ting, Wang, Cheng-Yi, Shiau, Chung-Wai, Tseng, Ling-Ming, Chen, Kuen-Feng
Publicado 2014

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy

por Chen, Kuen-Feng, Yen, Chueh-Chuan, Lin, Jen-Kou, Chen, Wei-Shone, Yang, Shung-Haur, Jiang, Jeng-Kai, Lan, Yuan-Tzu, Lin, Chun-Chi, Yu, Hui-Chuan, Hsu, Hui-Mei, Lin, Wen-Ling, Teng, Hao-Wei
Publicado 2015

Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis

por Su, Jung-Chen, Mar, Ai-Chung, Wu, Szu-Hsien, Tai, Wei-Tien, Chu, Pei-Yi, Wu, Chia-Yun, Tseng, Ling-Ming, Lee, Te-Chang, Chen, Kuen-Feng, Liu, Chun-Yu, Chiu, Hao-Chieh, Shiau, Chung-Wai
Publicado 2016